Seagen

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about
Seagen, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Seagen please access Flcube.comFineline Info & Tech (Flcube.com) provides you with comprehensive information about Seagen, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare.

SynRx Therapeutics' SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status
CompanyDrug

SynRx Therapeutics’ SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status

SynRx Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to SYN818, the company's proprietary Polθ (DNA polymerase theta) inhibitor, in combination with…

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer
CompanyDrug

Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer

Genmab's Tivdak Approved in Japan for Advanced Cervical Cancer Treatment
CompanyDrug

Genmab’s Tivdak Approved in Japan for Advanced Cervical Cancer Treatment

Zai Lab Submits TIVDAK BLA to China's NMPA for Cervical Cancer Treatment
CompanyDrug

Zai Lab Submits TIVDAK BLA to China’s NMPA for Cervical Cancer Treatment

GSK's Blenrep and Star Pharma's Topiramate Solution Target Priority Review in China
CompanyDrug

GSK’s Blenrep and Star Pharma’s Topiramate Solution Target Priority Review in China

CompanyDeals

Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC

CompanyDeals

Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics

Company

Pfizer’s $43 Billion Seagen Acquisition Closes Amid Lackluster 2024 Forecast

CompanyDrug

Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study

Show More